PRKAA2

Across TCGA pan-cancer cohorts, PRKAA2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PRKAA2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PRKAA2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PRKAA2 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and PDAC are the cancer types where PRKAA2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRKAA2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	−0.871	<.001	8	view →
LSCC	Male	III,IV	−0.554	<.001	7	view →
PDAC	All	All	−0.454	.001	5	view →
CCRCC	All	All	−0.130	.008	2	view →
COAD	All	All	−0.749	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PRKAA2–HNSC

Open the HNSC breakdown →